FDA Commissioner Confirmation Hearings To Focus On Agency Oversight
This article was originally published in The Gray Sheet
The Clinton Administration's nominee for FDA commissioner can expect during confirmation hearings a "detailed and exhaustive review" of the candidate's commitment to implementing the FDA Modernization Act, according to Jay Hawkins, health policy director of the Senate Labor and Human Resources Committee.
You may also be interested in...
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.